Recent Company News

• 05:02 PM ET Aug 18, 2025
  

  REGENXBIO announces FDA review extension of BLA for RGX-121 to treat patients with MPS II ($8.71, 0.00)

• 08:32 AM ET Aug 08, 2025
  

  Capricor Therapeutics announces Type A meeting scheduled with FDA ($8.07, 0.00)

• 11:09 PM ET Aug 06, 2025
  

  Nippon Shinyaku reports Q1 net income attributable ¥8.26B vs FactSet ¥5.79B [3 est, ¥5-6.44B] (¥3328.0000, +14)

• 06:54 AM ET Jul 25, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Macitentan Accord

• 12:00 AM ET Jun 23, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 11:00 PM ET Jun 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 01:10 AM ET Jul 08, 2025
  

  UCB to present 15 abstracts from its targeted neurology portfolio at the European Pediatric Neurology Society (EPNS) Congress, Munich, Germany, July 8-12, 2025 (€169.90, 0.00)

• 09:05 AM ET Jun 24, 2025
  

  Capricor Therapeutics provides regulatory update on Deramiocel BLA for Duchenne Muscular Dystrophy ($7.68, 0.00)